Q10 – former, mängder och forskningens gränser

Öppna källan

Entire official fact sheet main text including safety, disclaimer and source update; no linked trials

URL: https://www.nccih.nih.gov/health/coenzyme-q10
Publisher: NIH National Center for Complementary and Integrative Health
Source date: 2019-01
Captured: 2026-10-18T16:44:01.700362+00:00
Scope: Entire official fact sheet main text including safety, disclaimer and source update; no linked trials
Actual HTTP status: 200

Coenzyme Q10
© Thinkstock
Coenzyme Q10 (CoQ10) is a substance that is naturally present in the human body, with the highest levels in the heart, liver, kidneys, and pancreas. It is sold in the United States as a dietary supplement. Because CoQ10 has important functions in the body and because people with some diseases have reduced levels of this substance, researchers have been interested in finding out whether CoQ10 supplements might have health benefits.
Bottom Line
CoQ10 has not been shown to be of value in treating
cancer
, but it may reduce the risk of heart damage caused by one type of cancer chemotherapy drug.
Only a few studies have looked at whether CoQ10 might help prevent
heart disease
, and their results are inconclusive. Research on the effects of CoQ10 in heart failure is also inconclusive. However, there is evidence that CoQ10 may reduce the risk of some complications of heart surgery.
Although results of individual studies have varied, the overall scientific evidence does not support the idea that CoQ10 can reduce muscle pain caused by the cholesterol-lowering drugs known as statins.
The small amount of evidence currently available suggests that CoQ10 probably doesn’t have a meaningful effect on
blood pressure
.
A major National Institutes of Health-funded study showed that CoQ10, even in higher-than-usual doses, didn’t improve symptoms in patients with early
Parkinson’s disease
. A 2017 evaluation of this study and several other, smaller studies concluded that CoQ10 is not helpful for Parkinson’s symptoms.
CoQ10 has also been studied for a variety of other conditions, including amyotrophic lateral sclerosis (Lou Gehrig’s disease), Down syndrome, Huntington’s disease, and male infertility, but the research is too limited for any conclusions to be drawn.
Safety
No serious side effects of CoQ10 have been reported. Mild side effects such as insomnia or digestive upsets may occur.
CoQ10 may interact with the anticoagulant (blood thinner) warfarin and the diabetes drug insulin, and it may not be compatible with some types of cancer treatment.
For More Information
NCCIH Clearinghouse
The NCCIH Clearinghouse provides information on NCCIH and complementary and integrative health approaches, including publications and searches of Federal databases of scientific and medical literature. The Clearinghouse does not provide medical advice, treatment recommendations, or referrals to practitioners.
Toll-free in the U.S.:
1-888-644-6226
Telecommunications relay service (TRS):
7-1-1
Website:
https://www.nccih.nih.gov
Email:
info@nccih.nih.gov
(link sends email)
Know the Science
NCCIH and the National Institutes of Health (NIH) provide tools to help you understand the basics and terminology of scientific research so you can make well-informed decisions about your health.
Know the Science
features a variety of materials, including interactive modules, quizzes, and videos, as well as links to informative content from Federal resources designed to help consumers make sense of health information.
Explaining How Research Works
(NIH)
Know the Science: How To Make Sense of a Scientific Journal Article
Understanding Clinical Studies
(NIH)
PubMed®
A service of the National Library of Medicine, PubMed® contains publication information and (in most cases) brief summaries of articles from scientific and medical journals. For guidance from NCCIH on using PubMed, see
How To Find Information About Complementary Health Practices on PubMed
.
Website:
https://pubmed.ncbi.nlm.nih.gov/
This publication is not copyrighted and is in the public domain. Duplication is encouraged.
NCCIH has provided this material for your information. It is not intended to substitute for the medical expertise and advice of your health care provider(s). We encourage you to discuss any decisions about treatment or care with your health care provider. The mention of any product, service, or therapy is not an endorsement by NCCIH.
Last Updated:
January 2019

Öppna källan

Entire official public evidence-page article including plain-language summary and scientific abstract; not the full review report, appendices or trial originals

URL: https://www.cochrane.org/evidence/CD008684_coenzyme-q10-heart-failure
Publisher: Cochrane
Source date: 2021-02-03
Captured: 2026-10-18T16:44:37.494302+00:00
Scope: Entire official public evidence-page article including plain-language summary and scientific abstract; not the full review report, appendices or trial originals
Actual HTTP status: 200

Heart failure is a term used to describe the state that develops when the heart cannot maintain adequate cardiac output, or can do so only at the expense of overfilling the heart chambers. People with heart failure commonly experience a relapsing and remitting disease course, with periods of stability and episodes of decompensation (failure to cope with heart damage), leading to worsening symptoms that necessitate hospitalisation.
Treatment options for heart failure range from drugs to heart transplantation, with each having its own limitations. Coenzyme Q10 (or ubiquinone) has been suggested as a treatment option in some trials. Coenzyme Q10 is a non-prescription nutritional supplement. It is a fat-soluble molecule that has a role in energy production within the cells of the body. It may also have antioxidant properties.
Low levels of coenzyme Q10 may be related to the severity of heart failure. Coenzyme Q10 has been found in all tissues and organs in the body, with the highest concentrations in the heart. Emerging data have suggested that the harmful effects of reactive oxygen species (unstable molecules that contains oxygen and easily reacts with other molecules) are increased in people with heart failure. Because of its antioxidant activity, coenzyme Q10 may help to reduce these toxic effects, which damage the components of the cardiac cells, and disrupt cellular signalling. Coenzyme Q10 plays an important role in conducting signals within the heart muscle and in generating energy.The concentration of coenzyme Q10 has been inversely related to the severity of heart failure. Supplementation with coenzyme Q10 may improve heart failure. Coenzyme Q10 is sometimes used because it is thought to have an acceptable safety profile, with no significant side effects.
We conducted this review to assess the available evidence on the effects of coenzyme Q10 in people with heart failure. We included 11 randomised controlled trials, involving 1573 participants. They were relatively small, and followed up participants for a relatively short period of time. The analyses show that coenzyme Q10 probably reduces the risk of mortality from all causes, and hospitalisations due to heart failure. It may result in increased, or little or no difference in the risk of myocardial infarction, stroke, or adverse events. The effect of coenzyme Q10 on cardiac function and symptom improvement is uncertain.
The evidence, current to October 2020, is of a moderate quality at best, because of the high risk of bias in some of the included studies and the absence of precise and consistent results. There is currently no convincing evidence to support or refute the use of coenzyme Q10 for heart failure.
Related content
Coenzyme Q10 for High Blood Pressure
Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease
Stem cell treatment for chronic ischaemic heart disease and congestive heart failure
Read the full abstract
Background
Coenzyme Q10, or ubiquinone, is a non-prescription nutritional supplement. It is a fat-soluble molecule that acts as an electron carrier in mitochondria, and as a coenzyme for mitochondrial enzymes. Coenzyme Q10 deficiency may be associated with a multitude of diseases, including heart failure. The severity of heart failure correlates with the severity of coenzyme Q10 deficiency. Emerging data suggest that the harmful effects of reactive oxygen species are increased in people with heart failure, and coenzyme Q10 may help to reduce these toxic effects because of its antioxidant activity. Coenzyme Q10 may also have a role in stabilising myocardial calcium-dependent ion channels, and in preventing the consumption of metabolites essential for adenosine-5'-triphosphate (ATP) synthesis. Coenzyme Q10, although not a primary recommended treatment, could be beneficial to people with heart failure. Several randomised controlled trials have compared coenzyme Q10 to other therapeutic modalities, but no systematic review of existing randomised trials was conducted prior to the original version of this Cochrane Review, in 2014.
Objectives
To review the safety and efficacy of coenzyme Q10 in heart failure.
Search strategy
We searched CENTRAL, MEDLINE, Embase, Web of Science, CINAHL Plus, and AMED on 16 October 2020; ClinicalTrials.gov on 16 July 2020, and the ISRCTN Registry on 11 November 2019. We applied no language restrictions.
Selection criteria
We included randomised controlled trials of either parallel or cross-over design that assessed the beneficial and harmful effects of coenzyme Q10 in people with heart failure. When we identified cross-over studies, we considered data only from the first phase.
Data collection and analysis
We used standard Cochrane methods, assessed study risk of bias using the Cochrane 'Risk of bias' tool, and GRADE methods to assess the quality of the evidence. For dichotomous data, we calculated the risk ratio (RR); for continuous data, the mean difference (MD), both with 95% confidence intervals (CI). Where appropriate data were available, we conducted meta-analysis. When meta-analysis was not possible, we wrote a narrative synthesis. We provided a PRISMA flow chart to show the flow of study selection.
Main results
We included eleven studies, with 1573 participants, comparing coenzyme Q10 to placebo or conventional therapy (control). In the majority of the studies, sample size was relatively small. There were important differences among studies in daily coenzyme Q10 dose, follow-up period, and the measures of treatment effect. All studies had unclear, or high risk of bias, or both, in one or more bias domains. We were only able to conduct meta-analysis for some of the outcomes. None of the included trials considered quality of life, measured on a validated scale, exercise variables (exercise haemodynamics), or cost-effectiveness.
Coenzyme Q10 probably reduces the risk of all-cause mortality more than control (RR 0.58, 95% CI 0.35 to 0.95; 1 study, 420 participants; number needed to treat for an additional beneficial outcome (NNTB) 13.3; moderate-quality evidence).
There was low-quality evidence of inconclusive results between the coenzyme Q10 and control groups for the risk of myocardial infarction (RR 1.62, 95% CI 0.27 to 9.59; 1 study, 420 participants), and stroke (RR 0.18, 95% CI 0.02 to 1.48; 1 study, 420 participants).
Coenzyme Q10 probably reduces hospitalisation related to heart failure (RR 0.62, 95% CI 0.49 to 0.78; 2 studies, 1061 participants; NNTB 9.7; moderate-quality evidence).
Very low-quality evidence suggests that coenzyme Q10 may improve the left ventricular ejection fraction (MD 1.77, 95% CI 0.09 to 3.44; 7 studies, 650 participants), but the results are inconclusive for exercise capacity (MD 48.23, 95% CI -24.75 to 121.20; 3 studies, 91 participants); and the risk of developing adverse events (RR 0.70, 95% CI 0.45 to 1.10; 2 studies, 568 participants).
We downgraded the quality of the evidence mainly due to high risk of bias and imprecision.
Authors' conclusions
The included studies provide moderate-quality evidence that coenzyme Q10 probably reduces all-cause mortality and hospitalisation for heart failure. There is low-quality evidence of inconclusive results as to whether coenzyme Q10 has an effect on the risk of myocardial infarction, or stroke. Because of very low-quality evidence, it is very uncertain whether coenzyme Q10 has an effect on either left ventricular ejection fraction or exercise capacity. There is low-quality evidence that coenzyme Q10 may increase the risk of adverse effects, or have little to no difference.
There is currently no convincing evidence to support or refute the use of coenzyme Q10 for heart failure. Future trials are needed to confirm our findings.
Citation
Al Saadi T, Assaf Y, Farwati M, Turkmani K, Al-Mouakeh A, Shebli B, Khoja M, Essali A, Madmani ME. Coenzyme Q10 for heart failure. Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No.: CD008684. DOI: 10.1002/14651858.CD008684.pub3.
Authors
Al Saadi T
Assaf Y
Farwati M
Turkmani K
Al-Mouakeh A
Shebli B
Khoja M
Essali A
Madmani ME
Published
3 February 2021
Full review on the Cochrane Library

Öppna källan

Full current exact imported definitions of distinct identities; not an identity merge

{"id":"chebi-46245","version_id":"471336df-8f13-4eba-9ff9-c5f539c6bb9a","name":"coenzyme Q10","definition":"A ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the <i>E</i>- configuration."}

{"id":"chebi-64183","version_id":"3bac9e72-1eb9-43b5-bec1-052f164d53fd","name":"ubiquinol-10","definition":"A ubiquinol in which the polyprenyl substituent is decaprenyl."}

Läs produktdeklarationen på ActiQs

Koenzym Q10 (ubikinon), MCT-olja (kokosnöt, akaciagummi), vegetabilisk kapsel (pullulan), E-vitamin (d-alfa-tokoferolsuccinat), selen (selenmetionin).

Innehåll:	1 kapsel	DRI % *
Koenzym Q10	200 mg	
Selen	200 μg	363
Vitamin E	60 mg	500
MCT-olja	200 mg	

Läs produktdeklarationen på ActiQs

Fyllnadsmedel (mikrokristallin cellulosa), kapsel (cellulosa), Q10.

Innehåll:	1 kapsel
Q10	100 mg

Läs produktdeklarationen på ActiQs

Ubikinon, medellånga triglycerider (MCT), surhetsreglerande medel (kalciumkarbonat), emulgeringsmedel (solroslecitin), kapsel (TILAPIA, FISKGELATIN), bivax, färgämne (paprikaextrakt).

Innehåll:	1 kapsel	DRI % *
CoQ10 (ubikinon)	100 mg